The products were formulated for symptoms associated with autism spectrum disorder.
The HOPE® (HOPE 1 & 2) products were launched in Pennsylvania in May 2019 with the support of leading advocacy group HOPE Grows for Autism.
Notably, feedback from patients has consistently shown success with and acceptance of HOPE® and since its launch it has become a top-selling product in Ilera’s portfolio.
Plan is to launch early 2020
A key priority for Zelira post-merger will be to launch HOPE® into global markets from early 2020, with the aim of generating revenues in the first half of the year.
In the US, Zelira’s strategy will be to license HOPE® into multiple states using a virtual distribution model.
In ex-US markets, Zelira will leverage its existing network of suppliers and distributors to market HOPE® in different countries.
These include Germany, Australia and the UK, which together represent the fastest growing global markets.
Growing focus on autism
Autism is already a focus of Zelda’s making the HOPE® products a strategic fit.
Zelda has previously undertaken a pilot clinical study in Chile to assess the efficacy of medicinal cannabis formulations in children diagnosed with autism.
More recently, Zelda has funded one of the world’s largest observational studies to assess the real-world use and impact of medicinal cannabis in children with autism spectrum disorder.
Both studies have provided evidence that treatment with medicinal cannabis can improve behaviours associated with autism and data is being used to design an interventional trial.